Headlands Technologies LLC Buys Shares of 13,821 AbbVie Inc. $ABBV

Key Points

• Headlands Technologies acquired 13,821 AbbVie shares worth approximately $3.48 million, while institutional investors collectively own 70.23% of ABBV.
• AbbVie reported quarterly revenue of $16.99 billion and adjusted earnings of $3.65 per share, exceeding analyst expectations. The company reaffirmed third-quarter EPS guidance of $3.84–$3.88 and maintains a $1.73 quarterly dividend, yielding about 2.7%.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and a $275.95 price target, though Humira’s biosimilar-related decline remains a key headwind despite growth from Skyrizi, Rinvoq and the Apogee acquisition.

Headlands Technologies LLC acquired a new position in AbbVie Inc. (NYSE:ABBV - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 13,821 shares of the company's stock, valued at approximately $3,478,000.

A number of other institutional investors also recently bought and sold shares of ABBV. ACT Advisors LLC. raised its stake in AbbVie by 2.5% during the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after purchasing an additional 41 shares during the period. Willner & Heller LLC lifted its position in shares of AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after buying an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC boosted its stake in AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after buying an additional 43 shares during the last quarter. Fielder Capital Group LLC grew its holdings in AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock valued at $637,000 after buying an additional 43 shares in the last quarter. Finally, Leslie Global Wealth LLC increased its stake in AbbVie by 1.5% in the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock worth $751,000 after acquiring an additional 44 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Trading Down 1.5%

ABBV stock opened at $256.27 on Friday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The company has a 50-day moving average price of $254.66 and a 200 day moving average price of $230.06. The stock has a market cap of $452.78 billion, a PE ratio of 72.39, a P/E/G ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the firm posted $2.97 earnings per share. The business's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is currently 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.06% of the company's stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Analyst Upgrades and Downgrades

Several research firms have commented on ABBV. Morgan Stanley reiterated an "overweight" rating and set a $296.00 price objective on shares of AbbVie in a research report on Monday, August 3rd. Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Bank of America increased their price target on shares of AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a report on Friday, July 10th. Evercore set a $235.00 price target on AbbVie in a research report on Friday, May 15th. Finally, Citigroup boosted their price objective on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $275.95.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source